Search clinical trials for: Ensatinib

Total 903 results

Peking University Cancer Hospital & Institute
Betta Pharmaceuticals Co., Ltd.

Recruiting

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer (EFLRWR)

NSCLC Stage IV | NSCLC Stage IIIB | ALK Positive

China
Xcovery Holding Company, LLC

Completed

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Advanced Solid Tumors | Non-small Cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Pierre Fabre Medicament

Not yet recruiting

Treatment Patterns of Neratinib in HER2+ EBC in China

Breast Cancer

China
Puma Biotechnology, Inc.

Completed

Study Evaluating HKI-272 in Tumors

Breast Neoplasms

United States
Puma Biotechnology, Inc.

Completed

A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors

Tumors

Japan
Puma Biotechnology, Inc.

Completed

Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)

Healthy Subjects

United States
Puma Biotechnology, Inc.

Completed

Study Evaluating The Tolerability Of Multiple Doses Of HKI-272

Healthy Subjects

United States
Puma Biotechnology, Inc.

Completed

Study Evaluating HKI-272 Administered to Healthy Subjects

Healthy

United States
UNC Lineberger Comprehensive Cancer Center

No longer available

Single Subject Neratinib in Bladder Cancer (NRR)

Bladder Cancer

United States
Pierre Fabre Pharma GmbH
iOMEDICO AG; Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Active, not recruiting

Real-life Pan-HER-blockade With Neratinib (ELEANOR)

Breast Neoplasm

Austria, Germany, Switzerland
Bristol-Myers Squibb

Completed

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

Pharmacokinetic Study in Healthy Participants

United States
Sichuan University
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | ALK Fusion Protein Expression | Adjuvant Therapy
Betta Pharmaceuticals Co., Ltd.

Completed

Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers

Lung Cancer

China
Xcovery Holdings, Inc.

Completed

A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions

Bioequivalency

United States
Puma Biotechnology, Inc.

Completed

A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects

Healthy

United States
Puma Biotechnology, Inc.

Withdrawn

Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib

Healthy
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations (CVL009-2001)

NSCLC

China
Betta Pharmaceuticals Co., Ltd.
Fudan University

Unknown

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Brain Metastases | Lung Cancer, Nonsmall Cell

China
Fudan University
Betta Pharmaceuticals Co., Ltd.

Unknown

X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Nonsmall Cell Lung Cancer | Brain Metastases
Betta Pharmaceuticals Co., Ltd.

Completed

A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.

Non-Small Cell Lung Cancer

China
Fudan University

Active, not recruiting

Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Regina Elena Cancer Institute
University of Pisa; University of Roma La Sapienza; University of Turin, Italy; Istituto Oncologico Veneto IRCCS and other collaborators

Recruiting

Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer (Gisel)

Differentiated Thyroid Cancer | Gender

Italy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Bioequivalence Study of Dasatinib Tablet

Leukemia, Myelogenous, Chronic

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)

Italy, Poland, Singapore, United States, China, Ukraine
National Cancer Institute (NCI)

Withdrawn

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
Shandong New Time Pharmaceutical Co., LTD

Recruiting

the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC

Hepatocellular Carcinoma | Radiotherapy | Lenvatinib

China
CStone Pharmaceuticals

Active, not recruiting

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Spain, China, United States, Poland, Italy, Taiwan
National Cancer Institute (NCI)
NRG Oncology

Terminated

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Recurrent Uterine Corpus Cancer

United States
Xspray Pharma AB
QPS Bioserve India Pvt Limited

Completed

Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions

Biological Availability

India
Xcovery Holding Company, LLC

Active, not recruiting

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Non-small Cell Lung Cancer

Spain, United States, China, Korea, Republic of, Canada, Hong Kong, United Kingdom, Turkey, Belgium, France, Poland, Israel, Australia, Argentina, Brazil, Czechia, Germany, Italy, Netherlands, Peru, Russian Federation
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies

Advanced Solid Cancer

China
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Solid Tumors

United States, China, Belgium, Australia, Italy, Korea, Republic of, Germany, Netherlands, Poland, Romania, Thailand
Eisai Inc.

Completed

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Thyroid Cancer

United States, Australia, France, Poland, United Kingdom, Italy
Hyoung Jin Kang

Not yet recruiting

Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea (VHR ALL)

Acute Lymphoblastic Leukemia, Pediatric
Shanghai Zhongshan Hospital

Active, not recruiting

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
University Hospital, Angers

Completed

Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia (DasaCBF)

Acute Myelogenous Leukemia

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib (CML1113)

Chronic Myeloid Leukemia

Italy
Peking Union Medical College Hospital

Completed

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

Cholangiocarcinoma | Biomarker | Combinational Immunotherapy | Liver Neoplasm Malignant Primary

China
University of Pittsburgh

Completed

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Head and Neck Cancer | Non Small Cell Lung Cancer

United States
Puma Biotechnology, Inc.

Completed

Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects

Healthy

United States
Virginia Commonwealth University
GlaxoSmithKline; Puma Biotechnology, Inc.

Recruiting

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (iNNOVATE)

Ovarian Cancer | Advanced Solid Tumor

United States
Peking Union Medical College Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The Second Affiliated...

Recruiting

Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer

Recurrent Ovarian Carcinoma

China
Massachusetts Eye and Ear Infirmary
Eisai Inc.

Recruiting

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Advanced Cancer | Differentiated Thyroid Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

Breast Cancer | Metastatic Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Malignant Mesothelioma

United States
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute; Puma Biotechnology, Inc.

Withdrawn

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma

United States
Tianjin Medical University Second Hospital

Recruiting

Tislelizumab Plus Lenvatinib in Stage III-IV RCC (TILUR)

Advanced Kidney Cancer

China
Nanfang Hospital of Southern Medical University

Unknown

Early Conversion of Dasatinib in CML-CP Patients

Validity and Safety

China

Search clinical trials for: Ensatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations